In short
A new clinical trial is underway to assess the effectiveness of 2LHERP®, a medication containing Specific Nucleic Acid SNA-HER2, in treating recurrent orofacial herpes infections, commonly known as cold sores. This randomized, placebo-controlled, double-blind study aims to determine if 2LHERP® can reduce the frequency and severity of cold sore outbreaks in patients who experience frequent episodes.
At a glance
- Study Design
- Randomized, placebo-controlled, double-blind
- Medication
- 2LHERP® (containing Specific Nucleic Acid SNA-HER2)
- Primary Objective
- Reduce number of recurrent orofacial herpes episodes at 12 months
- Secondary Objectives
- Evaluate episodes at 6 months, time to first episode, duration, symptoms, rescue medication use, quality of life, safety
- Participant Age Range
- 16-80 years
- Inclusion Criteria
- 6+ episodes in previous 12 months, stable sexual relationship, effective contraception for women
- Exclusion Criteria
- Pregnancy, immunotherapy, recent suppressive antiviral therapy, lactose intolerance, severe immunodeficiency
- Treatment Duration
- 12 months
- Dosage Form
- Granules in capsules to be opened
- Maximum Daily Dose
- 380 mg
What is 2LHERP?
2LHERP is a medication designed to treat recurrent cold sores, also known as orofacial herpes infections. It comes in the form of granules in capsules that are meant to be opened before use. The medication contains several active ingredients, including:
- Deoxyribonucleic acid (DNA): The genetic material found in all living organisms
- Ribonucleic acid (RNA): A molecule similar to DNA that plays various roles in biological processes
- Specific Nucleic Acid SNA-HER1: Also known as SNA-HER1 or Specific Nucleic Acid - Herpes Simplex Type I Virus
- Specific Nucleic Acid SNA-HER2: Also known as SNA-HER2 or Specific Nucleic Acid - Herpes Simplex Type II Virus
- Specific Nucleic Acid SNA-HLA I: Also known as SNA-HLA I or Specific Nucleic Acid - Human Leucocyte Antigen Type I
- Specific Nucleic Acid SNA-HLA II: Also known as SNA-HLA II or Specific Nucleic Acid - Human Leucocyte Antigen Type II
What Conditions Does 2LHERP Treat?
2LHERP is specifically designed to treat recurrent orofacial herpes infections, commonly known as cold sores or fever blisters. These are painful, fluid-filled blisters that typically appear around the mouth or on the lips. They are caused by the herpes simplex virus (HSV), usually type 1 (HSV-1) or occasionally type 2 (HSV-2).
The medication is intended for patients who experience frequent outbreaks, specifically those who have had 6 or more episodes within a 12-month period.
How 2LHERP Works
While the exact mechanism of action is not fully explained in the provided information, 2LHERP appears to work by utilizing specific nucleic acids that target the herpes simplex virus and interact with the human immune system. The inclusion of SNA-HER1 and SNA-HER2 suggests that the medication is designed to address both HSV-1 and HSV-2 infections. The SNA-HLA I and SNA-HLA II components likely interact with the body's immune system, as HLA (Human Leukocyte Antigen) plays a crucial role in immune responses.
Clinical Trial Details
A clinical trial is being conducted to evaluate the effectiveness of 2LHERP. Here are some key details about the study:
- It is a Phase IV clinical trial, which means the medication is already marketed but is being further studied
- The study is randomized, placebo-controlled, and double-blind, ensuring reliable results
- The main objective is to evaluate how well 2LHERP reduces the number of recurrent cold sore episodes over a 12-month period
- Secondary objectives include comparing 2LHERP to a placebo in terms of:
- Number of episodes at 6 months
- Time to the first episode during treatment
- Duration of episodes
- Symptoms during relapses
- Use of rescue medication
- Impact on quality of life
- Safety issues
Eligibility Criteria
To participate in the clinical trial, patients must meet certain criteria:
Inclusion Criteria:
- Age: 16-80 years old
- History of 6 or more cold sore episodes in the past 12 months
- Women of childbearing age must use effective contraception
- Participants must be in a stable sexual relationship
- Ability to understand and follow study requirements
- Willingness to sign an informed consent form
Exclusion Criteria:
- Pregnant or breastfeeding women
- Patients on immunotherapy or who have received microimmunotherapy in the last 6 months
- Those who have used suppressive antiviral therapy in the last month or wish to continue such therapy
- Known lactose intolerance
- Recent participation in other clinical studies (within the last 3 months)
- Inability to commit to a 12-month follow-up period
- Severe immunodeficiency diseases, ongoing chemotherapy, radiotherapy, or corticosteroid therapy
- Use of certain homeopathic or herbal treatments
- Use of or addiction to recreational drugs
Expected Outcomes
The primary goal of the study is to measure the change in the number of cold sore episodes over 12 months compared to the baseline (number of episodes in the 12 months before starting treatment). Secondary outcomes being measured include:
- Remaining free from cold sores for 6 and 12 months after starting treatment
- Time until the first cold sore outbreak during treatment
- Average duration of cold sore episodes
- Pain levels during outbreaks
- Need for additional (rescue) medication
- Impact on quality of life
- Occurrence of adverse events (side effects)
Potential Benefits
If proven effective, 2LHERP could offer several benefits to patients with recurrent cold sores:
- Reduced frequency of cold sore outbreaks
- Shorter duration of cold sore episodes
- Less severe symptoms during outbreaks
- Improved quality of life
- Potentially fewer side effects compared to traditional antiviral medications (this would need to be confirmed by the study results)
Administration and Dosage
2LHERP is administered orally (by mouth) as granules in capsules that are meant to be opened before use. The maximum daily dose is 380 mg, with a maximum total dose of 68.4 g over the course of treatment. The treatment period can last up to 6 months.
It's important to note that these dosage details are based on the clinical trial information and may not reflect the final recommended dosage if the medication is approved for general use. Always follow the instructions provided by your healthcare provider when taking any medication.